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the most common type of porphyria, are severe abdominal
pain, dark urine, peripheral neuropathies, and seizure. Pain
is common in patients with AIP, suggesting the involvement
of small myelinated Ad and C fibers. Constant current
perception threshold (CPT) testing is related to direct
stimulation of myelinated and unmyelinated nerve fibers in
the skin. In this report, we present a case with intractable
AIP pain, which was well controlled by administering
gabapentin. We evaluated the pain-relief effect of gaba-
pentin by objective constant CPT testing.
A 28-year-old woman had intermittent, severe tingling
pain in her lower legs, abdominal colicky pain, nausea,
vomiting, and visual and auditory hallucinations since August
2010. In October 2011, she was admitted to a hospital for
abdominal pain and limb weakness. Her porphyrin biochem-
ical data [aminolevulinic acid (ALA): 70.91 mg/dL (reference
values: 1.3e7 mg/dL), porphobilinogen: 184.87 mg/dL
(reference values: 0e2 mg/dL)] obtained from 24-hour urine
collection were compatible with those for AIP. After hematin
use, she demonstrated rapid clinical and biochemical
improvement. Unfortunately, the chronic neuropathy pain
was not well controlled. Gabapentin was started at 300 mg/
day and was slowly titrated to 1800 mg/day to treat pain.
Objective constant CPTwas tested on the right index finger.
The patient were tested at three sinusoidal stimulation* Corresponding author. Department of Neurology, Chang Gung
Memorial Hospital and University, 199, Tun Hwa North Road, Taipei,
Taiwan.
E-mail address: cgrols@adm.cgmh.org.tw (L.-S. Ro).
0929-6646/$ - see front matter Copyright ª 2013, Elsevier Taiwan LLC
http://dx.doi.org/10.1016/j.jfma.2013.04.011frequencies (that selectively stimulated Ab, Ad, and C fibers
using a 2000-, 250-, and 5-Hz stimulus, respectively) in the
median nerve distribution. After gabapentin use, the neces-
sity of morphine or meperidine for acute pain decreased,
fewer seizure episodes occurred, and improvement in limb
pain was observed. The results are shown in Fig. 1.
The probable mechanisms of AIP-inducing neuropathy
are damage from free radicals, ALA neurotoxicity, or heme
deficiency in nervous tissue. Several analgesics, including
morphine, meperidine, and codeine, are used for AIP pain
management. Unfortunately, patients develop increased
tolerance and in our AIP case, the chronic neuropathy pain
was not well controlled. Gabapentin has been reported to
effectively control seizure in AIP without inducing porphy-
ric crisis because it does not induce cytochrome P450. In
addition, administration of gabapentin has been proven toFigure 1 A gabapentin dose-dependent effect on CPT
threshold.
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Treating neuropathic pain with gabapentin 579be effective in treating neuropathic pain.1 The CPT values
are useful in evaluating the effect of analgesics for
improving neuropathic pain after peripheral nerve injury.2
It had been reported with significance that the fre-
quencies are dependent on fiber diameter and function.
The threshold values in our CPT testing showed a dose-
dependent trend, with increases in 2000-, 250-, and 5-Hz
stimulation after gabapentin use. It has been hypothesized
that neuropathic pain in patients with AIP is due to gate
control dysfunction.3 Gabapentin was shown to cross the
bloodebrain barrier and show interactions with various
mechanisms, including an affinity to calcium channel sub-
unit, alteration of monoamine neurotransmitters and se-
rotonin in blood, and neuroprotection.1,4 Our study
suggests that the involvement of the central pain receptors
in the pain-control mechanism of gabapentin is more than
that of the peripheral pain receptors. The results obtainedin this study may provide an alternative for the evaluation
and management of neuropathic pain in patients with AIP.References
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